192 related articles for article (PubMed ID: 32036188)
1. The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation.
Wolff C; Dowd WN; Ali MM; McClellan C; Meinhofer A; Glos L; Mutter R; Rosenberg M; Schick A
Addict Behav; 2020 Jun; 105():106268. PubMed ID: 32036188
[TBL] [Abstract][Full Text] [Related]
2. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
Cheng HG; Coplan PM
Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
[TBL] [Abstract][Full Text] [Related]
3. Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin.
Beheshti D
Health Econ; 2019 Dec; 28(12):1449-1461. PubMed ID: 31715653
[TBL] [Abstract][Full Text] [Related]
4. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484
[TBL] [Abstract][Full Text] [Related]
5. The release of abuse-deterrent OxyContin and adolescent heroin use.
DiNardi M
Drug Alcohol Depend; 2021 Dec; 229(Pt B):109114. PubMed ID: 34638038
[TBL] [Abstract][Full Text] [Related]
6. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
7. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
[TBL] [Abstract][Full Text] [Related]
8. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
9. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
[TBL] [Abstract][Full Text] [Related]
10. Prescription painkiller misuse and the perceived risk of harm from using heroin.
Kapadia SN; Bao Y
Addict Behav; 2019 Jun; 93():141-145. PubMed ID: 30711666
[TBL] [Abstract][Full Text] [Related]
11. Trends in the Nonmedical Use of OxyContin, United States, 2006 to 2013.
Jones CM; Muhuri PK; Lurie PG
Clin J Pain; 2017 May; 33(5):452-461. PubMed ID: 27513641
[TBL] [Abstract][Full Text] [Related]
12. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
13. Overestimation of Prescription Pain Reliever Misuse and Heroin Use among Adults.
Kollin R; Resko SM; Ellis JD; Agius E
Subst Use Misuse; 2021; 56(4):552-558. PubMed ID: 33624560
[TBL] [Abstract][Full Text] [Related]
14. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C.
Powell D; Alpert A; Pacula RL
Health Aff (Millwood); 2019 Feb; 38(2):287-294. PubMed ID: 30715966
[TBL] [Abstract][Full Text] [Related]
15. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
[TBL] [Abstract][Full Text] [Related]
16. Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study.
Lundstrom EW; Dai Z; Groth CP; Hendricks B; Winstanley EL; Abate M; Smith GS
Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):4. PubMed ID: 38178238
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
18. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.
Sessler NE; Downing JM; Kale H; Chilcoat HD; Baumgartner TF; Coplan PM
Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1238-46. PubMed ID: 24916486
[TBL] [Abstract][Full Text] [Related]
19. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
[TBL] [Abstract][Full Text] [Related]
20. Prescription pain reliever misuse prevalence, correlates, and origin of possession throughout the life course.
Mowbray O; Quinn A
Addict Behav; 2015 Nov; 50():22-7. PubMed ID: 26093503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
